These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23254428)

  • 1. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.
    Moise PA; Amodio-Groton M; Rashid M; Lamp KC; Hoffman-Roberts HL; Sakoulas G; Yoon MJ; Schweitzer S; Rastogi A
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1192-200. PubMed ID: 23254428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
    Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
    JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant
    Yi YH; Wang JL; Yin WJ; Xu WH
    Microb Drug Resist; 2021 Aug; 27(8):1044-1056. PubMed ID: 33728980
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
    Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia.
    Moise PA; Sakoulas G; McKinnell JA; Lamp KC; DePestel DD; Yoon MJ; Reyes K; Zervos MJ
    Clin Ther; 2015 Jul; 37(7):1443-1453.e2. PubMed ID: 25982687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis.
    Kale-Pradhan PB; Giuliano C; Jongekrijg A; Rybak MJ
    Pharmacotherapy; 2020 Jul; 40(7):648-658. PubMed ID: 32533859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study.
    Wong D; Wong T; Romney M; Leung V
    BMC Infect Dis; 2016 May; 16():224. PubMed ID: 27215201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections.
    Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR
    Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bloodstream infection in patients with impaired renal function.
    Weston A; Golan Y; Holcroft C; Snydman DR
    Clin Infect Dis; 2014 Jun; 58(11):1533-9. PubMed ID: 24642554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
    Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
    Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
    Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
    Trials; 2018 May; 19(1):297. PubMed ID: 29843781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole.
    Avery LM; Steed ME; Woodruff AE; Hasan M; Rybak MJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5990-3. PubMed ID: 22869580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Use of High-dose Daptomycin in a Child With Staphylococcus aureus Endocarditis.
    Prabhudesai S; Kanjani A; Nambi PS; Gnanasambandam S; Ramachandran B
    Pediatr Infect Dis J; 2016 May; 35(5):517-8. PubMed ID: 27074655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature.
    Baxi SM; Chan D; Jain V
    Infection; 2015 Dec; 43(6):751-4. PubMed ID: 25805524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.
    Kullar R; McClellan I; Geriak M; Sakoulas G
    Pharmacotherapy; 2014 Jun; 34(6):582-9. PubMed ID: 24658897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
    Casapao AM; Jacobs DM; Bowers DR; Beyda ND; Dilworth TJ;
    Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.